Innovation Showcase returns to highlight SickKids technologies and innovators
Annual commercialization event offers attendees access to emerging therapeutic and diagnostic SickKids technologies with high potential for market disruption and clinical impact.
The SickKids Innovation Showcase is returning for its second year, bringing together the latest in cutting-edge innovation at The Hospital for Sick Children (SickKids) with investors who can help advance ideas with the potential to improve health outcomes for patients. Hosted by the Industry Partnerships & Commercialization office at SickKids, the SickKids Innovation Showcase celebrates some of the most advanced health and life sciences ideas from the labs and clinics of SickKids innovators.
Attendees, primarily made up early-stage investors, venture capitalists, as well as pharmaceutical and biotechnology firms, get unparalleled access to emerging therapeutic and diagnostic technologies with high potential for market disruption and clinical impact.
Last year, over 200 people tuned into the virtual event to learn about the most advanced life science opportunities from SickKids, as well as to hear perspectives from top industry experts. This year, the event features seven of the top opportunities ripe for partnerships.
The virtual Innovation Showcase will be held on Tuesday, May 17. The Innovation Showcase includes pitch presentations from biopharmaceutical and medical technology research leads, followed by question-and-answer sessions and networking opportunities to meet SickKids innovators. Innovators will also have the chance to secure $10,000 in funding for their research, based on the audience’s vote for best presentation of the day.
Interested in attending?
Visit the IP&C website for registration details, and to learn more about how we work with external partners to advance SickKids research.
Check out the innovators and technologies that will be featured at the SickKids Innovation Showcase.
Xi Huang, Ph.D.
Senior Scientist, Developmental and Stem Cell Biology
Canada Research Chair in Cancer Biophysics
Treating primary brain cancer using an ion channel complex-targeting peptide
Novel Treatments for Cystic Fibrosis: Moving beyond CFTR modulators
Senior Scientist, Genetics and Genome Biology Associate Director, The Centre for Applied Genomics
P. Lynne Howell, PhD
Senior Scientist, Molecular Medicine
Canada Research Chair in Structural Biology
Novel coatings and topical applications that prevent and eliminate bacterial and fungal biofilms
MATCH: Machine Learning-based robust assay to predict cardiotoxicity of pharmaceuticals
Chief, Anesthesia and Pain Medicine Curtis Joseph and Harold Groves Chair in Anesthesia and Pain Medicine Associate Chief of Perioperative Services Research Scientist, Molecular Medicine
Professor, Canada Research Chair in Micro and Nano Engineering Systems, Director, University of Toronto Robotics Institute
Adam Shlien, PhD, FCCMG
Senior Scientist, Genetics and Genome Biology
Canada Research Chair in Childhood Cancer Genomics
ML-based RNA analysis for cancer diagnosis, prognosis, and therapy guidance applications
Cynthia Hawkins, MD, PhD, FRCPC
Neuropathologist, Paediatric Laboratory Medicine
Senior Scientist, Cell Biology
Clinical development of liquid biopsy tools for cancer detection and monitoring
AtriumDB: Integrated AI/ML-based platform to store, recapitulate and interrogate waveform data
Co-Chair, Artificial Intelligence Medicine for Kids Staff Physician, Cardiology Project Investigator, Translational Medicine
Program Manager, Critical Care Medicine Technical Lead, Artificial Intelligence in Medicine (AIM)
To provide real-world investor perspective, the event features several experts from top life sciences investment firms across North America.
Director, External Science & Partnering at Novartis Institutes for BioMedical Research, Novartis Institutes for Biomedical Research